Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Pediatric Dermatology · Giant Congenital Melanocytic Nevus

Navigating Care: Surgical and Medical Options

At a Glance

Treatment for a Giant Congenital Melanocytic Nevus (GCMN) includes surgical options like serial excision and tissue expansion, though removal doesn't fully eliminate melanoma risk. Severe cases may utilize targeted therapies like MEK inhibitors, which require strict cardiac and eye monitoring.

Deciding how to manage a Large or Giant Congenital Melanocytic Nevus (LCMN/GCMN) is a deeply personal process that involves balancing medical, aesthetic, and psychological factors [1][2]. Because these nevi are unique to each child, there is no single “right” treatment path.

Surgical Approaches

Surgery is often considered to improve the appearance of the nevus, reduce symptoms like itching, or make it easier to monitor the skin [3][2]. Common techniques include:

  • Serial Excision: The surgeon removes a portion of the nevus and allows the surrounding healthy skin to heal and stretch over several months before removing more [4][5]. This relies on the natural elasticity of a child’s skin [4].
  • Tissue Expansion: A balloon-like device called an expander is placed under healthy skin near the nevus and gradually filled with saline [6][7]. This “grows” new healthy skin that can then be used to cover the area once the nevus is removed [8].
  • Skin Grafting: If a large area is removed and there isn’t enough nearby skin to cover it, a thin layer of healthy skin is taken from another part of the body (a donor site) and moved to the nevus site [3][9].

The Debate Over “Prophylactic” Surgery

In the past, many doctors recommended removing the entire nevus as soon as possible to prevent melanoma (prophylactic excision) [10][11]. Today, this approach is widely debated because:

  1. Risk remains: Even if every visible inch of the nevus is removed from the skin, the risk of melanoma is not completely eliminated [12][13]. This is because nevus cells often extend deeply into tissues beneath the skin—such as the fascia, muscle, or even bone—which cannot be safely surgically excised [12]. Melanoma can still develop in these deep tissues or within the central nervous system (NCM).
  2. Surgical Burden: Achieving “complete” removal of a giant nevus often requires dozens of surgeries, which carries its own physical and emotional risks for a developing child [14][2].
  3. Scarring: Surgery replaces the nevus with a scar. For some families, the scar is preferable, while others may prefer the original appearance of the nevus [15].

Psychosocial Considerations

The appearance of a large nevus can have a significant emotional impact on both the child and their parents [16][12]. While surgery can help some children feel more comfortable in social settings, research shows that “successful” surgery does not always lead to a better quality of life [15][17]. Psychological support, including connecting with other families through advocacy groups, is often just as important as medical treatment [16].

Emerging Medical Therapies

For complex cases—such as when the nevus cannot be removed surgically or when pigment cells are causing symptoms in the brain (NCM)—doctors are investigating new “targeted” medications [18][19].

  • MEK Inhibitors: Drugs like trametinib are designed to block the NRAS/MAPK pathway, which is the “growth switch” that is stuck in the “on” position in most GCMN [18][20].
  • Use Case and Monitoring: These are currently considered experimental and are typically used “off-label” or accessed through clinical trials for severe, symptomatic cases [20]. They require a rigorous screening and safety monitoring schedule. Because they carry risks of cardiac toxicity (such as decreased heart pumping function) and ocular toxicity (retinopathy), children on these medications must have regular echocardiograms (heart scans) and ophthalmology (eye) exams [21][22].

Management of GCMN is moving toward a more conservative, “patient-centered” model that prioritizes the child’s overall well-being and long-term monitoring over immediate, aggressive surgery [23][24].

Previous: Medical Imaging and Pathology | Next: Living with GCMN

Common questions in this guide

Does completely removing the nevus prevent melanoma?
No, removing the visible skin portion of a giant congenital melanocytic nevus does not completely eliminate the risk of melanoma. Nevus cells often extend deep into tissues like muscle or the central nervous system, where melanoma can still develop.
What is tissue expansion for GCMN?
Tissue expansion involves placing a balloon-like device under healthy skin near the nevus and gradually filling it with saline. This stretches and grows new healthy skin that can be used to cover the area once the nevus is surgically removed.
Are there medications to treat giant congenital melanocytic nevi?
Yes, doctors are investigating targeted medications like MEK inhibitors (such as trametinib) for severe or symptomatic cases. These drugs block the specific growth pathway causing the nevus, but they require rigorous monitoring for potential side effects.
What are the risks of using MEK inhibitors like trametinib?
MEK inhibitors carry risks of cardiac toxicity, such as decreased heart pumping function, and ocular toxicity. Children taking these medications require regular echocardiograms and ophthalmology exams to monitor for complications.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What are the primary goals of surgery for my child: is it focused on appearance, making monitoring easier, or symptom relief?
  2. 2.Does complete removal of the skin portion of the nevus truly eliminate the risk of melanoma for my child?
  3. 3.If we choose tissue expansion, what are the most common complications we should be prepared for?
  4. 4.At what age would you recommend starting or finishing these procedures to minimize the impact on my child's social development?
  5. 5.If we decide not to proceed with surgery, what does a long-term "watchful waiting" plan look like?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Thickness of melanocytes in giant congenital melanocytic nevus for complete surgical excision: clinicopathological evaluation of 117 lesions according to the area and size.

    Kim JY, Lee SY, Kwak Y, Kim BJ

    BMC surgery 2024; (24(1)):90 doi:10.1186/s12893-024-02362-x.

    PMID: 38491443
  2. 2

    Congenital Melanocytic Nevi.

    Nathan S, Smetona J, Naran S, Bauer BS

    Clinics in plastic surgery 2025; (52(2)):259-269 doi:10.1016/j.cps.2024.09.003.

    PMID: 39986887
  3. 3

    Serial Excision for the Treatment of Giant Congenital Melanocytic Nevus: The Vietnamese Way.

    Hong SN, Huu ND, Duy NN, et al.

    Open access Macedonian journal of medical sciences 2019; (7(2)):231-233 doi:10.3889/oamjms.2019.058.

    PMID: 30745967
  4. 4

    Serial excision surgery for giant dorsal congenital melanocytic nevus: Case report.

    Dung PTV, Son TT, Thuy TTH, Duy TT

    International journal of surgery case reports 2023; (106()):108152 doi:10.1016/j.ijscr.2023.108152.

    PMID: 37098292
  5. 5

    A successful serial excision surgery for congenital melanocytic nevus in a child: A case report.

    Al Sakka Amini R, Hakmi A, Hendi H, et al.

    International journal of surgery case reports 2025; (130()):111297 doi:10.1016/j.ijscr.2025.111297.

    PMID: 40253790
  6. 6

    Serial tissue expansion and excision for reconstruction of giant dorsal congenital melanocytic nevus: A case report.

    Le HP, Tran NT, Nguyen Tran BS, Le NTN

    SAGE open medical case reports 2024; (12()):2050313X241275330 doi:10.1177/2050313X241275330.

    PMID: 39165299
  7. 7

    Management of Congenital Melanocytic Nevus on Face Using Multiple Re-expansion Method: Aesthetic and Psychosocial Results.

    Lee H, Eom Y, Oh KS

    The Journal of craniofacial surgery 2019; (30(8)):2385-2389 doi:10.1097/SCS.0000000000006000.

    PMID: 31609959
  8. 8

    Tissue expansion in the treatment of giant congenital melanocytic nevi of the upper extremity.

    Ma T, Fan K, Li L, et al.

    Medicine 2017; (96(13)):e6358 doi:10.1097/MD.0000000000006358.

    PMID: 28353563
  9. 9

    A Case of Giant Congenital Melanocytic Nevus Treated with Combination Therapy of Autologous Mesh-skin Grafts and Cultured Epithelial Autografts.

    Im S, Yamanaka H, Tsuge I, et al.

    Plastic and reconstructive surgery. Global open 2021; (9(6)):e3613 doi:10.1097/GOX.0000000000003613.

    PMID: 34104617
  10. 10

    A large-scale collection of giant congenital melanocytic nevi: Clinical and histopathological characteristics.

    Wu M, Yu Q, Gao B, et al.

    Experimental and therapeutic medicine 2020; (19(1)):313-318 doi:10.3892/etm.2019.8198.

    PMID: 31853305
  11. 11

    The outcome of using different surgical modalities and laser therapy in the treatment of small- and medium-sized congenital melanocytic nevi: a systematic review.

    ALMutairi HM, Al-Hothali GI

    International journal of dermatology 2020; (59(5)):535-542 doi:10.1111/ijd.14727.

    PMID: 31792950
  12. 12

    Giant congenital melanocytic nevi.

    Escandón-Pérez S, Landeta-Sa AP, González-Jasso Y, Arenas-Guzmán R

    Boletin medico del Hospital Infantil de Mexico 2019; (76(6)):251-258 doi:10.24875/BMHIM.18000103.

    PMID: 31769436
  13. 13

    Skin-related quality of life in children and adolescents with congenital melanocytic naevi - an analysis of self- and parent reports.

    Neuhaus K, Landolt MA, Theiler M, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2020; (34(5)):1105-1111 doi:10.1111/jdv.16131.

    PMID: 31803958
  14. 14

    Pemphigus vulgaris possibly associated with application of a tissue expander in a patient with Crohn's disease and primary sclerosing cholangitis.

    Badavanis G, Pasmatzi E, Kapranos N, et al.

    Acta dermatovenerologica Alpina, Pannonica, et Adriatica 2019; (28(4)):173-176.

    PMID: 31855271
  15. 15

    Surgical outcomes and psychosocial impact of giant congenital melanocytic nevus surgery: A single-center case series of 136 patients.

    Carmen Ceballos-Rodríguez M, Redondo P, Tomás-Velázquez A, et al.

    Journal of pediatric surgery 2021; (56(11)):2113-2117 doi:10.1016/j.jpedsurg.2020.12.023.

    PMID: 33461742
  16. 16

    Psychosocial Experiences in Children With Congenital Melanocytic Nevus on the Face and Their Parents Throughout the Tissue Expansion Treatment.

    Zhang C, Wu L, Zhao S, et al.

    The Journal of craniofacial surgery 2022; (33(3)):754-758 doi:10.1097/SCS.0000000000008151.

    PMID: 34538792
  17. 17

    Quality of Life in Chinese Patients With Large Congenital Melanocytic Nevi.

    Wang H, Yu Q, Li Q, Wang Z

    Frontiers in pediatrics 2022; (10()):784660 doi:10.3389/fped.2022.784660.

    PMID: 35281247
  18. 18

    Mosaic BRAF Fusions Are a Recurrent Cause of Congenital Melanocytic Nevi Targetable by MAPK Pathway Inhibition.

    Martin SB, Polubothu S, Bruzos AL, et al.

    The Journal of investigative dermatology 2024; (144(3)):593-600.e7 doi:10.1016/j.jid.2023.06.213.

    PMID: 37716647
  19. 19

    Melanoma in congenital melanocytic naevi.

    Kinsler VA, O'Hare P, Bulstrode N, et al.

    The British journal of dermatology 2017; (176(5)):1131-1143 doi:10.1111/bjd.15301.

    PMID: 28078671
  20. 20

    Targeted treatment of hypophosphatemia with trametinib in HRAS-related mosaic RASopathy.

    Mirza A, Rossi C, Kulozik A, et al.

    Orphanet journal of rare diseases 2025; (20(1)):339 doi:10.1186/s13023-025-03801-5.

    PMID: 40611284
  21. 21

    Real-world pharmacokinetics of trametinib in pediatric low-grade glioma.

    Pagnot L, Granger I, Guitton J, et al.

    Cancer chemotherapy and pharmacology 2025; (95(1)):35 doi:10.1007/s00280-025-04761-0.

    PMID: 39998657
  22. 22

    Impaired Bone Healing and Fracture Complications during Limb Lengthening in a Neurofibromatosis Type 1 Patient Receiving Selumetinib: Case Report and Literature Review.

    Safari Z, Tirta M, Rahbek O, Kold S

    Journal of orthopaedic case reports 2026; (16(2)):221-227 doi:10.13107/jocr.2026.v16.i02.6810.

    PMID: 41669024
  23. 23

    Case Report: Prenatal ultrasound presentation of congenital melanocytic nevus syndrome.

    Shi Z, Sun T, Yin J, et al.

    Frontiers in pediatrics 2024; (12()):1466999 doi:10.3389/fped.2024.1466999.

    PMID: 39776646
  24. 24

    Updates in the Management of Congenital Melanocytic Nevi.

    Mologousis MA, Tsai SY, Tissera KA, et al.

    Children (Basel, Switzerland) 2024; (11(1)) doi:10.3390/children11010062.

    PMID: 38255375

This page explains surgical and medical options for GCMN for informational purposes only. It does not replace professional medical advice. Always consult your child's pediatric dermatologist or surgeon to determine the safest treatment plan.

Get notified when new evidence is published on Large/giant congenital melanocytic nevus.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.